http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 08:45:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/PROPANC+Biopharma+CEO+visits+European+CDMO+for+PRP+drug+production/26651173.html <p>Propanc Biopharma, Inc. (NASDAQ: PPCB) announced that its Chief Executive Officer, James Nathanielsz, toured a European contract development and manufacturing organization's GMP facility in preparation for production of the company's lead drug candidate, PRP, according to a press release.</p> <p>PRP is described as a fixed combination of two proenzymes, trypsinogen and chymotrypsinogen, administered by intravenous injection once weekly. The drug is intended for use in a Phase 1b, first-in-human clinical study enrolling 30 to 40 patients with advanced solid tumor cancers.</p> <p>During the visit, Propanc's research and development team and personnel from the CDMO discussed proposed project timelines, which include the following http://www.streetinsider.com/FDA/PROPANC+Biopharma+CEO+visits+European+CDMO+for+PRP+drug+production/26651173.html Tue, 16 Jun 2026 08:45:22 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/FDA/PROPANC+Biopharma+CEO+visits+European+CDMO+for+PRP+drug+production/26651173.html <p>Propanc Biopharma, Inc. (NASDAQ: PPCB) announced that its Chief Executive Officer, James Nathanielsz, toured a European contract development and manufacturing organization's GMP facility in preparation for production of the company's lead drug candidate, PRP, according to a press release.</p> <p>PRP is described as a fixed combination of two proenzymes, trypsinogen and chymotrypsinogen, administered by intravenous injection once weekly. The drug is intended for use in a Phase 1b, first-in-human clinical study enrolling 30 to 40 patients with advanced solid tumor cancers.</p> <p>During the visit, Propanc's research and development team and personnel from the CDMO discussed proposed project timelines, which include the following http://www.streetinsider.com/FDA/PROPANC+Biopharma+CEO+visits+European+CDMO+for+PRP+drug+production/26651173.html Tue, 16 Jun 2026 08:45:22 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/FDA/PROPANC+Biopharma+CEO+visits+European+CDMO+for+PRP+drug+production/26651173.html <p>Propanc Biopharma, Inc. (NASDAQ: PPCB) announced that its Chief Executive Officer, James Nathanielsz, toured a European contract development and manufacturing organization's GMP facility in preparation for production of the company's lead drug candidate, PRP, according to a press release.</p> <p>PRP is described as a fixed combination of two proenzymes, trypsinogen and chymotrypsinogen, administered by intravenous injection once weekly. The drug is intended for use in a Phase 1b, first-in-human clinical study enrolling 30 to 40 patients with advanced solid tumor cancers.</p> <p>During the visit, Propanc's research and development team and personnel from the CDMO discussed proposed project timelines, which include the following http://www.streetinsider.com/FDA/PROPANC+Biopharma+CEO+visits+European+CDMO+for+PRP+drug+production/26651173.html Tue, 16 Jun 2026 08:45:22 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/FDA/PROPANC+Biopharma+CEO+visits+European+CDMO+for+PRP+drug+production/26651173.html <p>Propanc Biopharma, Inc. (NASDAQ: PPCB) announced that its Chief Executive Officer, James Nathanielsz, toured a European contract development and manufacturing organization's GMP facility in preparation for production of the company's lead drug candidate, PRP, according to a press release.</p> <p>PRP is described as a fixed combination of two proenzymes, trypsinogen and chymotrypsinogen, administered by intravenous injection once weekly. The drug is intended for use in a Phase 1b, first-in-human clinical study enrolling 30 to 40 patients with advanced solid tumor cancers.</p> <p>During the visit, Propanc's research and development team and personnel from the CDMO discussed proposed project timelines, which include the following http://www.streetinsider.com/FDA/PROPANC+Biopharma+CEO+visits+European+CDMO+for+PRP+drug+production/26651173.html Tue, 16 Jun 2026 08:45:22 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/FDA/PPCB+CEO+visits+European+CDMO+ahead+of+PRP+drug+manufacturing+plan/26651172.html <p>Propanc Biopharma, Inc. (NASDAQ: PPCB) announced that Chief Executive Officer James Nathanielsz toured a European contract development and manufacturing organization's facility in preparation for the production of the company's lead drug candidate, PRP, ahead of a planned Phase 1b, First-In-Human clinical study.</p> <p>According to a press release, the visit included discussions between Propanc's research and development team and CDMO personnel on project timelines. The company outlined the following target dates for production milestones: preproduction in August 2026, an engineering run in October 2026, and GMP manufacture commencing in December 2026.</p> <p>PRP is described as a fixed combination of two proenzymes, trypsinogen and http://www.streetinsider.com/FDA/PPCB+CEO+visits+European+CDMO+ahead+of+PRP+drug+manufacturing+plan/26651172.html Tue, 16 Jun 2026 08:45:14 -0400 PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651165.html <p><strong>Pre-production, Engineering Run and GMP Manufacture of PRP in 2026</strong></p><p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651165.html Tue, 16 Jun 2026 08:45:00 -0400 PPCB PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651165.html <p><strong>Pre-production, Engineering Run and GMP Manufacture of PRP in 2026</strong></p><p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651165.html Tue, 16 Jun 2026 08:45:00 -0400 PPCB PPCB http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651165.html <p><strong>Pre-production, Engineering Run and GMP Manufacture of PRP in 2026</strong></p><p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651165.html Tue, 16 Jun 2026 08:45:00 -0400 PPCB PPCB http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651165.html <p><strong>Pre-production, Engineering Run and GMP Manufacture of PRP in 2026</strong></p><p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651165.html Tue, 16 Jun 2026 08:45:00 -0400 PPCB PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html <p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. In addition to touring the facility, the joint http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html Tue, 16 Jun 2026 08:45:00 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html <p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. In addition to touring the facility, the joint http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html Tue, 16 Jun 2026 08:45:00 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html <p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. In addition to touring the facility, the joint http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html Tue, 16 Jun 2026 08:45:00 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html <p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. In addition to touring the facility, the joint http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html Tue, 16 Jun 2026 08:45:00 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html <p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. In addition to touring the facility, the joint http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html Tue, 16 Jun 2026 08:45:00 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html <p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. In addition to touring the facility, the joint http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html Tue, 16 Jun 2026 08:45:00 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html <p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. In addition to touring the facility, the joint http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html Tue, 16 Jun 2026 08:45:00 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html <p>MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company’s lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. In addition to touring the facility, the joint http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Tours+European+CDMO+%26amp%3B+Plans+for+GMP+Production+of+PRP+for+Phase+1b%2C+FIH+Study/26651166.html Tue, 16 Jun 2026 08:45:00 -0400 A.36447039 O.13604272 O.16607186 PPCB http://www.streetinsider.com/Stock+Buybacks/Propanc+Biopharma+authorizes+%245+million+stock+buyback+program/26633094.html <p>Propanc Biopharma, Inc. (NASDAQ: PPCB) announced it has approved a share repurchase program authorizing the company to buy back up to $5 million of its common stock.</p> <p>The biopharmaceutical company, which focuses on developing treatments for chronic diseases including cancer, may repurchase shares through various methods including open market purchases, privately negotiated transactions, and block trades. The program does not require the company to acquire any specific number of shares and may be modified or suspended at any time.</p> <p>"The management team believes we are entering a transformative stage for the Company," said James Nathanielsz, Propanc's Chief Executive Officer. He cited the http://www.streetinsider.com/Stock+Buybacks/Propanc+Biopharma+authorizes+%245+million+stock+buyback+program/26633094.html Thu, 11 Jun 2026 08:30:32 -0400 PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma+Authorizes+%245.0+Million+Share+Repurchase+Program/26633056.html <p><strong>Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment &amp; Prevention of Metastatic Cancer from Solid Tumors</strong></p><p>MELBOURNE, Australia, June 11, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has approved a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock.</p> <p>“With our recent advancements of the Company’s lead asset, PRP, towards entering the clinic with a novel, first-in-class http://www.streetinsider.com/Press+Releases/Propanc+Biopharma+Authorizes+%245.0+Million+Share+Repurchase+Program/26633056.html Thu, 11 Jun 2026 08:30:00 -0400 PPCB PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma+Authorizes+%245.0+Million+Share+Repurchase+Program/26633056.html <p><strong>Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment &amp; Prevention of Metastatic Cancer from Solid Tumors</strong></p><p>MELBOURNE, Australia, June 11, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has approved a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock.</p> <p>“With our recent advancements of the Company’s lead asset, PRP, towards entering the clinic with a novel, first-in-class http://www.streetinsider.com/Press+Releases/Propanc+Biopharma+Authorizes+%245.0+Million+Share+Repurchase+Program/26633056.html Thu, 11 Jun 2026 08:30:00 -0400 PPCB PPCB http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma+Authorizes+%245.0+Million+Share+Repurchase+Program/26633056.html <p><strong>Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment &amp; Prevention of Metastatic Cancer from Solid Tumors</strong></p><p>MELBOURNE, Australia, June 11, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has approved a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock.</p> <p>“With our recent advancements of the Company’s lead asset, PRP, towards entering the clinic with a novel, first-in-class http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma+Authorizes+%245.0+Million+Share+Repurchase+Program/26633056.html Thu, 11 Jun 2026 08:30:00 -0400 PPCB PPCB http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma+Authorizes+%245.0+Million+Share+Repurchase+Program/26633056.html <p><strong>Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment &amp; Prevention of Metastatic Cancer from Solid Tumors</strong></p><p>MELBOURNE, Australia, June 11, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has approved a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock.</p> <p>“With our recent advancements of the Company’s lead asset, PRP, towards entering the clinic with a novel, first-in-class http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma+Authorizes+%245.0+Million+Share+Repurchase+Program/26633056.html Thu, 11 Jun 2026 08:30:00 -0400 PPCB PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Attends+Keynote+Address%2C+%E2%80%9CRejuvenation+and+Health%3A+Science+for+an+Ageing+Society%2C%E2%80%9D+at+the+University+of+Granada%2C+Spain/26586312.html <p><strong>Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing</strong></p><p>MELBOURNE, Australia, June 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, attended a keynote address, “Rejuvenation and Health: Science for an Ageing Society,” the title of a new edition of 'Dialogues with Society', an event organized by the Social Council of the University of Granada (UGR), held at the historical Hospital Real, Granada, http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Attends+Keynote+Address%2C+%E2%80%9CRejuvenation+and+Health%3A+Science+for+an+Ageing+Society%2C%E2%80%9D+at+the+University+of+Granada%2C+Spain/26586312.html Tue, 02 Jun 2026 05:30:00 -0400 PPCB PPCB http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Attends+Keynote+Address%2C+%E2%80%9CRejuvenation+and+Health%3A+Science+for+an+Ageing+Society%2C%E2%80%9D+at+the+University+of+Granada%2C+Spain/26586312.html <p><strong>Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing</strong></p><p>MELBOURNE, Australia, June 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, attended a keynote address, “Rejuvenation and Health: Science for an Ageing Society,” the title of a new edition of 'Dialogues with Society', an event organized by the Social Council of the University of Granada (UGR), held at the historical Hospital Real, Granada, http://www.streetinsider.com/Press+Releases/Propanc+Biopharma%E2%80%99s+CEO+Attends+Keynote+Address%2C+%E2%80%9CRejuvenation+and+Health%3A+Science+for+an+Ageing+Society%2C%E2%80%9D+at+the+University+of+Granada%2C+Spain/26586312.html Tue, 02 Jun 2026 05:30:00 -0400 PPCB PPCB http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Attends+Keynote+Address%2C+%E2%80%9CRejuvenation+and+Health%3A+Science+for+an+Ageing+Society%2C%E2%80%9D+at+the+University+of+Granada%2C+Spain/26586312.html <p><strong>Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing</strong></p><p>MELBOURNE, Australia, June 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, attended a keynote address, “Rejuvenation and Health: Science for an Ageing Society,” the title of a new edition of 'Dialogues with Society', an event organized by the Social Council of the University of Granada (UGR), held at the historical Hospital Real, Granada, http://www.streetinsider.com/Globe+Newswire/Propanc+Biopharma%E2%80%99s+CEO+Attends+Keynote+Address%2C+%E2%80%9CRejuvenation+and+Health%3A+Science+for+an+Ageing+Society%2C%E2%80%9D+at+the+University+of+Granada%2C+Spain/26586312.html Tue, 02 Jun 2026 05:30:00 -0400 PPCB PPCB